Presented by
In collaboration with

Date
3 & 5 March 2021

Time
13:00 - 18:25 (GMT+9, JPN)

Register now
  • About Us
  • Agenda
  • Speakers
  • Partners

About Us

The Healthcare Industries Division, Commerce and Service Industry Policy Group, under the Ministry of Economy, Trade and Industry (METI) of the Government of Japan, is planning focused sector-specific webinars for promoting quality and productivity in Japanese Industry in association with a Public-Private Partnership of Japan, Medical Excellence JAPAN jointly with Nomura Research Institute (NRI), and industry – Academia bodies. It will be held on March 3rd and March 5th this year.

Hospitals can look forward to learn about the ASEAN healthcare landscape from ASEAN organisation itself, Deloitte Asian healthcare expert, WHO, the ASEAN regulatory agencies and hospital associations.

 

Presented by


Ministry
METI’s mission is to develop Japan’s economy and industry by focusing on promoting economic vitality in private companies and smoothly advancing external economic relationships, and to secure stable and efficient supply of energy and mineral resources.

In collaboration with



Medical Excellence JAPAN (MEJ) is a public-private partnership, which was established to serve as the central organizational hub to facilitate overseas expansion in the healthcare and medical care sector, based on one of Japan’s growth strategies.

MEJ is an organization that promotes international health cooperation by joint with governments, medical communities, academic organizations encompassing associations of medical sciences, and the healthcare industry.




Nomura Research Institute, Ltd. (NRI) was born out of the 1988 merger between the former Nomura Research Institute, Ltd., founded in 1965 as Japan’s first fully-fledged private sector think tank, and Nomura Computer Systems Co., Ltd., which was established in 1966 and achieved the first business applications for commercial computers in Japan.

Since its inception, NRI has always been on the cutting edge. By advising policy proposals and corporate strategies or developing new systems, we have always strived to push the boundaries and explore new horizons. At NRI, we are dedicated to helping our clients manage the complexity of today’s markets with confidence.

Agenda

Japan timezone (GMT+9)

  • Day 1
  • Day 2

Wednesday, March 3

13:00 - 13:05
Opening Remarks: Ministry of Economy, Trade, and Industries

Takuma Inamura, Director, Healthcare industries division, Ministry of Economy, Trade and Industry (METI), Government of Japan

  • Takuma Inamura

    Director, Healthcare industries division, Ministry of Economy, Trade and  Industry (METI), Government of Japan

    Takuma Inamura Director, Healthcare industries division, Ministry of Economy, Trade and  Industry (METI), Government of Japan

    Mr. Inamura joined METI in 1998 and has mostly worked on policy-making in areas such as energy, international trade, and manufacturing industries. Before taking up his current position, he was the director in charge of a drastic revision of the Japanese legislation on the electricity supply business to enable the cost-effective deployment of renewable energy and sustainable investment in the power grid system. Holds a BA in Law from the University of Tokyo and MA from the Fletcher School of Law and Diplomacy, Tufts University.
13:05 - 13:10
Welcome Remarks: Medical Excellence Japan

Dr Tatsuya Kondo, Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA)

  • Dr Tatsuya Kondo

    Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA)

    Dr Tatsuya Kondo Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA)

    Tatsuya Kondo, M.D., Ph.D., is Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA). As the Chief Executive of PMDA from 2008-2018, he directed all operations, including drug relief services, reviews of medical products, and post-marketing safety. He was also a significant player of ICMRA among the world's top Drug Regulatory Agencies. He has reformed all around the faculties of PMDA, basically on the three major initiatives, which are “the PMDA’s newly established Philosophy”, “Regulatory Science”, and the respect for regulatory harmonization. Prior to joining PMDA, he spent most of his career as a neurosurgeon after he graduated from the Medical Department, the University of Tokyo in 1968. He experienced not only so many kinds of neurosurgical operations but also as a surgeon-scientist so many kinds of R&D. He invented the stereotactic radiosurgery system, which synchronizes with breathing in 1992 and discovered the new FGF-9 from an operated brain tumor that has the thrombocyte growth activity in 1993. These inventions and discoveries were never implemented in society. It was because it was too early. He has been every time curious about the scientific study and the promotion of technology. Dr. Kondo has wide-ranging experience overseas, such as fellowship in Max-Planck Institute, Germany for biological research in 1977, and visiting surgeon in China-Japan Friendship Hospital, Beijing in 1987 to establish Department of Neurosurgery under JICA project. Currently, he has been serving as the Advisor on Health and Medical Strategy for the Cabinet Secretariat of the Japanese Government for six years. Moreover, he has also been an advisory member of the Center for Regulatory Authority (CoRE) of Singapore from 2014. When it comes to priorities, he expresses strong intentions about the healthcare issues he hopes multi-stakeholders will tackle, as the CEO of MEJ, he becomes a leading force of the momentum toward healthcare reform; “the fourth dimensions” revolutionary healthcare reform plan.
13:30 - 14:00
Keynote 1: Shaping global health beyond COVID-19: challenges and opportunities for ASEAN and Japan

Dr Hiroki Nakatani, former Assistant Director General, World Health Organisation Japan

  • Dr Hiroki Nakatani

    Project Professor, Keio-APRU Ageing Research Hub

    Dr Hiroki Nakatani Project Professor, Keio-APRU Ageing Research Hub

    In the past four years, Dr. Hiroki Nakatani has been Project Professor, Global Research Institute at Keio University and Invited Professor at Osaka University Post Graduate School of Medicine. Also, Dr. Nakatani has engaged himself with various national and international institutions as Member, Executive Board, WHO; Minister’s Advisor on International Affairs, Ministry of Health, Labour and Welfare; Chair, Board of Directors, Global Health Innovative Technology Fund (GHIT Fund); Project Director, Hub on Population Ageing, Association of Pacific Rim Universities( APRU); Member, Board of Directors, National Center for Global Health and Medicine; and Director, Human Resource Strategy Center for Global Health with grant from the Ministry. He is a veteran public health specialist over 40 years, who started his career at the Ministry of Health, Labour and Welfare. Dr Nakatani’s worked extensively in the area of health policy, public health, international health and health science and technology. Part of his national career includes assignment for Hiroshima Prefecture where he was in charge of integration of health and welfare services in preparation for rapidly coming ageing society. With regards to international career, he represented the Government at various international conferences and meetings. Dr.Nakatani served WHO Headquarters twice. First as the Policy Analysist in the Department of Human Resource for Health from April 1988 to March 1993 and recently as Assistant Director-General of WHO from March 2007 to May 2015. He led the largest technical cluster comprising HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases. During his tenure, the morbidity and mortality of these three major infections showed trends of decline, and a few tropical diseases were on track towards elimination and even eradication in case of dracunculiasis (guinea worm disease). Dr. Nakatani received his M.D. from Keio University School of Medicine, M.H.P.Ed from the University of New South Wales, and Ph.D. from Keio University.
14:10 - 14:40
Keynote 2: Progress of ASEAN healthcare sector despite the pandemics

Mr. Ashish Mahajan, Partner, Lifesciences & Healthcare Sector, Deloitte

  • Ashish Mahajan

    Partner, Lifesciences & Healthcare Sector, Deloitte

    Ashish Mahajan Partner, Lifesciences & Healthcare Sector, Deloitte

    Ashish is a partner in Deloitte Consulting based in SEA. He manages technology and digital transformation engagements for Deloitte clients across Pharma, Medtech and Hospital sector. Ashish has worked on multiple ‘’first’’ projects each time challenging boundaries and focussing to deliver tangible benefits. These projects included SSCs, telehealth programs, Patient support programs, Personalised healthcare initiatives in diverse markets of Japan, SEA and India. His passion is work at the intersection of patient impact, digital tech and healthcare.
14:50 - 15:00
Introduction to Regulatory Session
  • Dr Tatsuya Kondo

    Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA)

    Dr Tatsuya Kondo Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA)

    Tatsuya Kondo, M.D., Ph.D., is Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA). As the Chief Executive of PMDA from 2008-2018, he directed all operations, including drug relief services, reviews of medical products, and post-marketing safety. He was also a significant player of ICMRA among the world's top Drug Regulatory Agencies. He has reformed all around the faculties of PMDA, basically on the three major initiatives, which are “the PMDA’s newly established Philosophy”, “Regulatory Science”, and the respect for regulatory harmonization. Prior to joining PMDA, he spent most of his career as a neurosurgeon after he graduated from the Medical Department, the University of Tokyo in 1968. He experienced not only so many kinds of neurosurgical operations but also as a surgeon-scientist so many kinds of R&D. He invented the stereotactic radiosurgery system, which synchronizes with breathing in 1992 and discovered the new FGF-9 from an operated brain tumor that has the thrombocyte growth activity in 1993. These inventions and discoveries were never implemented in society. It was because it was too early. He has been every time curious about the scientific study and the promotion of technology. Dr. Kondo has wide-ranging experience overseas, such as fellowship in Max-Planck Institute, Germany for biological research in 1977, and visiting surgeon in China-Japan Friendship Hospital, Beijing in 1987 to establish Department of Neurosurgery under JICA project. Currently, he has been serving as the Advisor on Health and Medical Strategy for the Cabinet Secretariat of the Japanese Government for six years. Moreover, he has also been an advisory member of the Center for Regulatory Authority (CoRE) of Singapore from 2014. When it comes to priorities, he expresses strong intentions about the healthcare issues he hopes multi-stakeholders will tackle, as the CEO of MEJ, he becomes a leading force of the momentum toward healthcare reform; “the fourth dimensions” revolutionary healthcare reform plan.
15:10 - 15:40
Medical Device Regulation Updates: Philippines

Effective communication w/ Industries for fast and proper access to patients

  • Maria Cecilia C. Matienzo

    Director, Center for Device Regulation, Radiation Health, and Research, Food and Drug Administration, Department of Health, Philippines

    Maria Cecilia C. Matienzo Director, Center for Device Regulation, Radiation Health, and Research, Food and Drug Administration, Department of Health, Philippines

    Director, Center for Device Regulation, Radiation Health, and Research, Food and Drug Administration, Department of Health, Philippines
15:50 - 16:20
Medical Device Regulation Updates: Malaysia

Effective communication with Industries for fast and proper access to patients

  • Salbiah Binti Yaakop

    Director of Policy, Code and Standard Division, Ministry of Health Malaysia

    Salbiah Binti Yaakop Director of Policy, Code and Standard Division, Ministry of Health Malaysia

    Ms Salbiah Yaakop is currently attached with the Medical Device Authority, Ministry of Health Malaysia, as the Director of Policy, Codes and Standards Division. Here, her main functions are development of regulatory documents, policies, guidance documents, guidelines, managing international affairs and inter-agency agenda, industry assistance, events and specific projects; performing registration and licensing evaluations and verifications; and giving trainings and consultancy. She often represents MDA in other government and non-government meetings and programs and initiatives. She is currently the AHWP/GHWP TC Chair, AHWP/GHWP WG 8 Chair on Standards for Medical Devices, Convenor for ISO/TC 210/WG 7 on Good Engineering Maintenance Management, and Chairperson of various Guidance Document Development Committees in Medical Device Authority. She is also a member of various Industry Standards Committees, Technical Committees and Working Groups related to medical devices in the national standards system. Prior to her current field of work, she has almost 10 years of working experience in the automotive industry, working in the fields of mechanical, industrial and process engineering, and procurement. Ms Salbiah Yaakop graduated with a BSc in Biomedical Engineering from Marquette University, USA. In total, she has more than 28 years of working experience.
  • Wan Nurhalimah Binti Wan Abdullah

    Assistant Director, Corporate Communication Unit, Medical Device Authority Malaysia

    Wan Nurhalimah Binti Wan Abdullah Assistant Director, Corporate Communication Unit, Medical Device Authority Malaysia

    Assistant Director from Corporate Communication Unit, Medical Device Authority Malaysia, Master in Mass Communication from University Teknologi Mara (UiTM) Malaysia
16:30 - 17:00
Medical Device Regulation Updates: Indonesia

Indonesia: Effective communication with Industries for fast and proper access to patients

  • Lupi Trilaksono

    Deputy Director of Local Medical Devices and Household Health Products, MOH Indonesia

    Lupi Trilaksono Deputy Director of Local Medical Devices and Household Health Products, MOH Indonesia

    Deputy Director of Local Medical Devices and Household Health Products, MOH Indonesia
17:10 - 17:40
Medical Device Regulation Updates: Vietnam

Effective communication with Industries for fast and proper access to patients

  • Nguyen Minh Tuan

    Director General of Medical Eqpt & Construction at Vietnam

    Nguyen Minh Tuan Director General of Medical Eqpt & Construction at Vietnam

    Director General of Medical Eqpt & Construction at Vietnam
17:50 - 18:20
Medical Device Regulation Updates: Thai and PMDA Closing Remarks

Effective communication with Industries for fast and proper access to patients

  • Dr Sirinmas Katchamart

    Pharmacist, Senior Professional Level from Medical Devices Control Division, Thai FDA

    Dr Sirinmas Katchamart Pharmacist, Senior Professional Level from Medical Devices Control Division, Thai FDA

    Pharmacist, Senior Professional Level from Medical Devices Control Division, Thai FDA
  • Dr. Junko Sato

    Director, Office of International Program at Pharmaceuticals and Medical Devices Agency

    Dr. Junko Sato Director, Office of International Program at Pharmaceuticals and Medical Devices Agency

    Dr. Junko Sato is an Office Director of Office of International Program at Pharmaceuticals and Medical Devices Agency (PMDA). She joined Regulatory Agency in 1998. She became a review director of Office of New Drug in 2004 and moved to Office of Safety in 2009 to develop a new risk management system through life cycle of drugs. During the period, she visited U.S.FDA as a guest reviewer from September 2002 to March 2003. From May 2012 to April 2014, she was dispatched to EMA as MHLW/PMDA Liaison. She enhanced collaboration between EMA and MHLW/PMDA and brought a huge success as the liaison. She contributed to some global harmonization activities, for example, ICH, CIOMS etc. She also contributes many DIA activities. She received DIA Outstanding Service Award 2010. She led the activities of PMDA Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC) including planning/conduct of all the trainings, and contributes to building stronger bilateral relationship with ASEAN countries by playing the role as the contact point. She also works for AMR project like EMA-FDA-PMDA tripartite meeting to discuss convergence on approaches for the evaluation of antibacterial drugs. She is an Infection Control Doctor certificated by The Japanese Association of Infectious Disease.

Friday, March 5

13:00 - 13:10
Opening and Welcome Remarks: Medical Excellence Japan
  • Dr Tatsuya Kondo

    Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA)

    Dr Tatsuya Kondo Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA)

    Tatsuya Kondo, M.D., Ph.D., is Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA). As the Chief Executive of PMDA from 2008-2018, he directed all operations, including drug relief services, reviews of medical products, and post-marketing safety. He was also a significant player of ICMRA among the world's top Drug Regulatory Agencies. He has reformed all around the faculties of PMDA, basically on the three major initiatives, which are “the PMDA’s newly established Philosophy”, “Regulatory Science”, and the respect for regulatory harmonization. Prior to joining PMDA, he spent most of his career as a neurosurgeon after he graduated from the Medical Department, the University of Tokyo in 1968. He experienced not only so many kinds of neurosurgical operations but also as a surgeon-scientist so many kinds of R&D. He invented the stereotactic radiosurgery system, which synchronizes with breathing in 1992 and discovered the new FGF-9 from an operated brain tumor that has the thrombocyte growth activity in 1993. These inventions and discoveries were never implemented in society. It was because it was too early. He has been every time curious about the scientific study and the promotion of technology. Dr. Kondo has wide-ranging experience overseas, such as fellowship in Max-Planck Institute, Germany for biological research in 1977, and visiting surgeon in China-Japan Friendship Hospital, Beijing in 1987 to establish Department of Neurosurgery under JICA project. Currently, he has been serving as the Advisor on Health and Medical Strategy for the Cabinet Secretariat of the Japanese Government for six years. Moreover, he has also been an advisory member of the Center for Regulatory Authority (CoRE) of Singapore from 2014. When it comes to priorities, he expresses strong intentions about the healthcare issues he hopes multi-stakeholders will tackle, as the CEO of MEJ, he becomes a leading force of the momentum toward healthcare reform; “the fourth dimensions” revolutionary healthcare reform plan.
13:20 - 13:55
Keynote: Noncommunicable disease services during the COVID-19 in the South-East Asia Region: Reflections, World Health Organization - Regional Office for South-East Asia (WHO - SEARO)
  • Dr Gampo Dorji

    Technical Officer, Non-communicable Diseases, Southeast Asia, WHO

    Dr Gampo Dorji Technical Officer, Non-communicable Diseases, Southeast Asia, WHO

    Dr Gampo Dorji is a public health professional with more than twenty years of experience. He currently works as a technical officer for Non-communicable Diseases in the WHO South-East Asia Regional Office in New Delhi, India. He is a citizen of Bhutan. He has received a Doctor in Public Health (Dr.PH), Boston University, MA, USA, Master of Public Health (MPH), Bloomberg School of Public Health, Johns Hopkins University, USA and Bachelors in Medicine and Bachelors in Surgery (MBBS) from India. He began his career as a primary health care physician and worked in remote areas in Bhutan. Later he worked in the Ministry of Health in Bhutan overseeing several important national programmes including HIV/AIDS, and NCDs. He joined WHO in 2016. He has deep interest in public health education and engages in coaching and mentoring of public health students and health workers in the South-East Asia Region.
14:10 - 14:45
Vietnam policies on NCDs prevention and control amid the COVID-19 pandemic
  • Dr Vuong Anh Duong

    Deputy Director, Department of Medical Service Administration, MOH Vietnam

    Dr Vuong Anh Duong Deputy Director, Department of Medical Service Administration, MOH Vietnam

    Dr Vuong Anh Duong was born in 1970 in Phutho Province of Vietnam. He graduated as a medical doctor in Hanoi Medical University, Vietnam in 1993. He gained his Dr Vuong Anh Duong graduated as a medical doctor in Hanoi Medical University, Vietnam in 1993 he gained his Master Degree: Master of Business Administration on Hospital Management from Donau University Krems, Austria in and PhD in Healthcare Management Department, Berlin University of Technology, Berlin, Germany. Dr Vuong Anh Duong has over 20 year working experiences in Provincial Department of Health and Ministry of Health. At the MOH, he is Deputy Director of Department of Medical Service Administration (MSA). His main interests are some policy areas as Hospital Service management, Hospital service quality assessment/acreditation, Health economic evaluation, Health Technology Assesstment, Non-communicable Disease Prevention and Control. At the ministerial level, He participates in developing health policies that focus on improving the quality of hospital service; hospital service management, Hospital quality assessment/ acreditation, Health economic evaluation, Health Technology Assesstment, Non-communicable Disease Prevention and Control, Guideline on diagnosis and treatment of NCD. He has 10 publications on international Scientific Journal on some different areas: cost counting; health ecnomic evaluation, HTA, epidemiology.
15:00 - 15:15
Health Policy Update 2021, Thailand: NCDs management and its impact from the COVID-19 on health care systems
  • Dr Sasithorn Tangsawad

    Director, Bureau of Non-Communicable Disease, Ministry of Public Health

    Dr Sasithorn Tangsawad Director, Bureau of Non-Communicable Disease, Ministry of Public Health

    Director, Bureau of Non-Communicable Disease, Ministry of Public Health
16:00 - 17:15
Introduction to MEJ - Japan Hospital Association - Thai Private Hospital Association - Rapid fire presentation: Allm, Ubie, PHC/Epredia, Tokai kiki & Matsunaga/Kaigo Life
  • Introduction to MEJ & Japan Hospital Association
  • Outlook into 2021
  • Chronic disease management
  • Japanese medical device companies rapid fire presentations
  • Dr Tsuneo Sakai

    President, Japan Hospital Cooperative, Inc.

    Dr Tsuneo Sakai President, Japan Hospital Cooperative, Inc.

    Dr. Sakai is President of Japan Hospital Cooperative, Inc. and Honorary President of Japan Hospital Association、former President of Seirei Hamamatsu General Hospital in Hamamatsu, Japan. He is lifelong Honorary Member of the International Hospital Federation. He specializes in Neurosurgery. He graduated from Chiba University School of Medicine in 1970 and had a full neurosurgical training at State University of New York, Upstate Medical Center, Syracuse, USA.
  • Dr Minoru Akiyama

    Executive Director, Medical Excellence JAPAN

    Dr Minoru Akiyama Executive Director, Medical Excellence JAPAN

    Executive Director, Medical Excellence JAPAN
  • Dr Surapong Ambhanwong, FRCS. DABNS, FICS

    Chief Advisor, Thailand Private Hospital Association

    Dr Surapong Ambhanwong, FRCS. DABNS, FICS Chief Advisor, Thailand Private Hospital Association

    Dr. Surapong graduated M.D. from Siriraj Hospital, Mahidol University in 1962.  His a neurosurgeon with a post graduate degree from McGill University in Canada   Dr. Surapong has also had long experience ihospital management together with international business for medical and health promotion and has represented Thailand as such.   During 1999-2003 Dr. Surapong was the Chairperson of the Private Hospital Association (PHA) in Thailand from 1999-2003. He was tasked to promote medical tourism by the Thai government during this time. He worked closely with the government and presented on behalf of the government and the private medical sector on various occasions until the present time,   Dr. Surapong is the Chief Advisor for the Private Hospital Association’s business development, and is also working as a member of few committees for Board of Trade of Thailand.   PHA has 307 private hospital members, out of total of 386 private hospitals in  Thailand. 
17:30 - 18:25
Indonesia Private Hospital Association - Rapid fire presentations: PT Asa Bestari Citta, Hazuko Medical, Tanita, Sysmex & Sumitomo Heavy Industry
  • Introduction
  • Outlook into 2021
  • Chronic disease management
  • Japanese medical device companies rapid fire presentations
  • Leona Karnali

    Head, International Relations Department, ARSSI Indonesia’s Private Hospital Association

    Leona Karnali Head, International Relations Department, ARSSI Indonesia’s Private Hospital Association

    Leona leads Primaya Hospital Group, a leading private hospital group operating 10 hospitals located strategically across Indonesia. Prior to her appointment as CEO, she was the COO for the past 5 years leading the hospital’s transformation in human capital, procurement, marketing and international relationships. Her expertise and experience range from operational and strategic management to risk and financial management through previous work experiences in education, banking, and private equity. Leona graduated with a Master of Science degree from Massachusetts Institute of Technology. She is a CFA charterholder and is a certified FRM.

Speakers


  • Takuma Inamura
    Mr. Inamura joined METI in 1998 and has mostly...

    Takuma Inamura Director, Healthcare industries division, Ministry of Economy, Trade and  Industry (METI), Government of Japan

    Mr. Inamura joined METI in 1998 and has mostly worked on policy-making in areas such as energy, international trade, and manufacturing industries. Before taking up his current position, he was the director in charge of a drastic revision of the Japanese legislation on the electricity supply business to enable the cost-effective deployment of renewable energy and sustainable investment in the power grid system. Holds a BA in Law from the University of Tokyo and MA from the Fletcher School of Law and Diplomacy, Tufts University.
  • Dr Tatsuya Kondo
    Tatsuya Kondo, M.D., Ph.D., is Chief Executive Officer of...

    Dr Tatsuya Kondo Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA)

    Tatsuya Kondo, M.D., Ph.D., is Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA). As the Chief Executive of PMDA from 2008-2018, he directed all operations, including drug relief services, reviews of medical products, and post-marketing safety. He was also a significant player of ICMRA among the world's top Drug Regulatory Agencies. He has reformed all around the faculties of PMDA, basically on the three major initiatives, which are “the PMDA’s newly established Philosophy”, “Regulatory Science”, and the respect for regulatory harmonization. Prior to joining PMDA, he spent most of his career as a neurosurgeon after he graduated from the Medical Department, the University of Tokyo in 1968. He experienced not only so many kinds of neurosurgical operations but also as a surgeon-scientist so many kinds of R&D. He invented the stereotactic radiosurgery system, which synchronizes with breathing in 1992 and discovered the new FGF-9 from an operated brain tumor that has the thrombocyte growth activity in 1993. These inventions and discoveries were never implemented in society. It was because it was too early. He has been every time curious about the scientific study and the promotion of technology. Dr. Kondo has wide-ranging experience overseas, such as fellowship in Max-Planck Institute, Germany for biological research in 1977, and visiting surgeon in China-Japan Friendship Hospital, Beijing in 1987 to establish Department of Neurosurgery under JICA project. Currently, he has been serving as the Advisor on Health and Medical Strategy for the Cabinet Secretariat of the Japanese Government for six years. Moreover, he has also been an advisory member of the Center for Regulatory Authority (CoRE) of Singapore from 2014. When it comes to priorities, he expresses strong intentions about the healthcare issues he hopes multi-stakeholders will tackle, as the CEO of MEJ, he becomes a leading force of the momentum toward healthcare reform; “the fourth dimensions” revolutionary healthcare reform plan.
  • Ashish Mahajan
    Ashish is a partner in Deloitte Consulting based in...

    Ashish Mahajan Partner, Lifesciences & Healthcare Sector, Deloitte

    Ashish is a partner in Deloitte Consulting based in SEA. He manages technology and digital transformation engagements for Deloitte clients across Pharma, Medtech and Hospital sector. Ashish has worked on multiple ‘’first’’ projects each time challenging boundaries and focussing to deliver tangible benefits. These projects included SSCs, telehealth programs, Patient support programs, Personalised healthcare initiatives in diverse markets of Japan, SEA and India. His passion is work at the intersection of patient impact, digital tech and healthcare.
  • Dr Gampo Dorji
    Dr Gampo Dorji is a public health professional with...

    Dr Gampo Dorji Technical Officer, Non-communicable Diseases, Southeast Asia, WHO

    Dr Gampo Dorji is a public health professional with more than twenty years of experience. He currently works as a technical officer for Non-communicable Diseases in the WHO South-East Asia Regional Office in New Delhi, India. He is a citizen of Bhutan. He has received a Doctor in Public Health (Dr.PH), Boston University, MA, USA, Master of Public Health (MPH), Bloomberg School of Public Health, Johns Hopkins University, USA and Bachelors in Medicine and Bachelors in Surgery (MBBS) from India. He began his career as a primary health care physician and worked in remote areas in Bhutan. Later he worked in the Ministry of Health in Bhutan overseeing several important national programmes including HIV/AIDS, and NCDs. He joined WHO in 2016. He has deep interest in public health education and engages in coaching and mentoring of public health students and health workers in the South-East Asia Region.
  • Dr Hiroki Nakatani
    In the past four years, Dr. Hiroki Nakatani has...

    Dr Hiroki Nakatani Project Professor, Keio-APRU Ageing Research Hub

    In the past four years, Dr. Hiroki Nakatani has been Project Professor, Global Research Institute at Keio University and Invited Professor at Osaka University Post Graduate School of Medicine. Also, Dr. Nakatani has engaged himself with various national and international institutions as Member, Executive Board, WHO; Minister’s Advisor on International Affairs, Ministry of Health, Labour and Welfare; Chair, Board of Directors, Global Health Innovative Technology Fund (GHIT Fund); Project Director, Hub on Population Ageing, Association of Pacific Rim Universities( APRU); Member, Board of Directors, National Center for Global Health and Medicine; and Director, Human Resource Strategy Center for Global Health with grant from the Ministry. He is a veteran public health specialist over 40 years, who started his career at the Ministry of Health, Labour and Welfare. Dr Nakatani’s worked extensively in the area of health policy, public health, international health and health science and technology. Part of his national career includes assignment for Hiroshima Prefecture where he was in charge of integration of health and welfare services in preparation for rapidly coming ageing society. With regards to international career, he represented the Government at various international conferences and meetings. Dr.Nakatani served WHO Headquarters twice. First as the Policy Analysist in the Department of Human Resource for Health from April 1988 to March 1993 and recently as Assistant Director-General of WHO from March 2007 to May 2015. He led the largest technical cluster comprising HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases. During his tenure, the morbidity and mortality of these three major infections showed trends of decline, and a few tropical diseases were on track towards elimination and even eradication in case of dracunculiasis (guinea worm disease). Dr. Nakatani received his M.D. from Keio University School of Medicine, M.H.P.Ed from the University of New South Wales, and Ph.D. from Keio University.
  • Dr Indri Yogyaswari
    Head of Program & Information Division, Ministry of Health...

    Dr Indri Yogyaswari Head of Program & Information Division, Ministry of Health Indonesia

    Head of Program & Information Division, Ministry of Health Indonesia
  • Dr. Junko Sato
    Dr. Junko Sato is an Office Director of Office...

    Dr. Junko Sato Director, Office of International Program at Pharmaceuticals and Medical Devices Agency

    Dr. Junko Sato is an Office Director of Office of International Program at Pharmaceuticals and Medical Devices Agency (PMDA). She joined Regulatory Agency in 1998. She became a review director of Office of New Drug in 2004 and moved to Office of Safety in 2009 to develop a new risk management system through life cycle of drugs. During the period, she visited U.S.FDA as a guest reviewer from September 2002 to March 2003. From May 2012 to April 2014, she was dispatched to EMA as MHLW/PMDA Liaison. She enhanced collaboration between EMA and MHLW/PMDA and brought a huge success as the liaison. She contributed to some global harmonization activities, for example, ICH, CIOMS etc. She also contributes many DIA activities. She received DIA Outstanding Service Award 2010. She led the activities of PMDA Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC) including planning/conduct of all the trainings, and contributes to building stronger bilateral relationship with ASEAN countries by playing the role as the contact point. She also works for AMR project like EMA-FDA-PMDA tripartite meeting to discuss convergence on approaches for the evaluation of antibacterial drugs. She is an Infection Control Doctor certificated by The Japanese Association of Infectious Disease.
  • Dr Minoru Akiyama
    Executive Director, Medical Excellence JAPAN

    Dr Minoru Akiyama Executive Director, Medical Excellence JAPAN

    Executive Director, Medical Excellence JAPAN
  • Dr Sasithorn Tangsawad
    Director, Bureau of Non-Communicable Disease, Ministry of Public Health

    Dr Sasithorn Tangsawad Director, Bureau of Non-Communicable Disease, Ministry of Public Health

    Director, Bureau of Non-Communicable Disease, Ministry of Public Health
  • Dr Sirinmas Katchamart
    Pharmacist, Senior Professional Level from Medical Devices Control Division,...

    Dr Sirinmas Katchamart Pharmacist, Senior Professional Level from Medical Devices Control Division, Thai FDA

    Pharmacist, Senior Professional Level from Medical Devices Control Division, Thai FDA
  • Dr Surapong Ambhanwong, FRCS. DABNS, FICS
    Dr. Surapong graduated M.D. from Siriraj Hospital, Mahidol University...

    Dr Surapong Ambhanwong, FRCS. DABNS, FICS Chief Advisor, Thailand Private Hospital Association

    Dr. Surapong graduated M.D. from Siriraj Hospital, Mahidol University in 1962.  His a neurosurgeon with a post graduate degree from McGill University in Canada   Dr. Surapong has also had long experience ihospital management together with international business for medical and health promotion and has represented Thailand as such.   During 1999-2003 Dr. Surapong was the Chairperson of the Private Hospital Association (PHA) in Thailand from 1999-2003. He was tasked to promote medical tourism by the Thai government during this time. He worked closely with the government and presented on behalf of the government and the private medical sector on various occasions until the present time,   Dr. Surapong is the Chief Advisor for the Private Hospital Association’s business development, and is also working as a member of few committees for Board of Trade of Thailand.   PHA has 307 private hospital members, out of total of 386 private hospitals in  Thailand. 
  • Dr Tsuneo Sakai
    Dr. Sakai is President of Japan Hospital Cooperative, Inc....

    Dr Tsuneo Sakai President, Japan Hospital Cooperative, Inc.

    Dr. Sakai is President of Japan Hospital Cooperative, Inc. and Honorary President of Japan Hospital Association、former President of Seirei Hamamatsu General Hospital in Hamamatsu, Japan. He is lifelong Honorary Member of the International Hospital Federation. He specializes in Neurosurgery. He graduated from Chiba University School of Medicine in 1970 and had a full neurosurgical training at State University of New York, Upstate Medical Center, Syracuse, USA.
  • Dr Vuong Anh Duong
    Dr Vuong Anh Duong was born in 1970 in...

    Dr Vuong Anh Duong Deputy Director, Department of Medical Service Administration, MOH Vietnam

    Dr Vuong Anh Duong was born in 1970 in Phutho Province of Vietnam. He graduated as a medical doctor in Hanoi Medical University, Vietnam in 1993. He gained his Dr Vuong Anh Duong graduated as a medical doctor in Hanoi Medical University, Vietnam in 1993 he gained his Master Degree: Master of Business Administration on Hospital Management from Donau University Krems, Austria in and PhD in Healthcare Management Department, Berlin University of Technology, Berlin, Germany. Dr Vuong Anh Duong has over 20 year working experiences in Provincial Department of Health and Ministry of Health. At the MOH, he is Deputy Director of Department of Medical Service Administration (MSA). His main interests are some policy areas as Hospital Service management, Hospital service quality assessment/acreditation, Health economic evaluation, Health Technology Assesstment, Non-communicable Disease Prevention and Control. At the ministerial level, He participates in developing health policies that focus on improving the quality of hospital service; hospital service management, Hospital quality assessment/ acreditation, Health economic evaluation, Health Technology Assesstment, Non-communicable Disease Prevention and Control, Guideline on diagnosis and treatment of NCD. He has 10 publications on international Scientific Journal on some different areas: cost counting; health ecnomic evaluation, HTA, epidemiology.
  • Leona Karnali
    Leona leads Primaya Hospital Group, a leading private hospital...

    Leona Karnali Head, International Relations Department, ARSSI Indonesia’s Private Hospital Association

    Leona leads Primaya Hospital Group, a leading private hospital group operating 10 hospitals located strategically across Indonesia. Prior to her appointment as CEO, she was the COO for the past 5 years leading the hospital’s transformation in human capital, procurement, marketing and international relationships. Her expertise and experience range from operational and strategic management to risk and financial management through previous work experiences in education, banking, and private equity. Leona graduated with a Master of Science degree from Massachusetts Institute of Technology. She is a CFA charterholder and is a certified FRM.
  • Lupi Trilaksono
    Deputy Director of Local Medical Devices and Household Health...

    Lupi Trilaksono Deputy Director of Local Medical Devices and Household Health Products, MOH Indonesia

    Deputy Director of Local Medical Devices and Household Health Products, MOH Indonesia
  • Maria Cecilia C. Matienzo
    Director, Center for Device Regulation, Radiation Health, and Research,...

    Maria Cecilia C. Matienzo Director, Center for Device Regulation, Radiation Health, and Research, Food and Drug Administration, Department of Health, Philippines

    Director, Center for Device Regulation, Radiation Health, and Research, Food and Drug Administration, Department of Health, Philippines
  • Nguyen Minh Tuan
    Director General of Medical Eqpt & Construction at Vietnam

    Nguyen Minh Tuan Director General of Medical Eqpt & Construction at Vietnam

    Director General of Medical Eqpt & Construction at Vietnam
  • Salbiah Binti Yaakop
    Ms Salbiah Yaakop is currently attached with the Medical...

    Salbiah Binti Yaakop Director of Policy, Code and Standard Division, Ministry of Health Malaysia

    Ms Salbiah Yaakop is currently attached with the Medical Device Authority, Ministry of Health Malaysia, as the Director of Policy, Codes and Standards Division. Here, her main functions are development of regulatory documents, policies, guidance documents, guidelines, managing international affairs and inter-agency agenda, industry assistance, events and specific projects; performing registration and licensing evaluations and verifications; and giving trainings and consultancy. She often represents MDA in other government and non-government meetings and programs and initiatives. She is currently the AHWP/GHWP TC Chair, AHWP/GHWP WG 8 Chair on Standards for Medical Devices, Convenor for ISO/TC 210/WG 7 on Good Engineering Maintenance Management, and Chairperson of various Guidance Document Development Committees in Medical Device Authority. She is also a member of various Industry Standards Committees, Technical Committees and Working Groups related to medical devices in the national standards system. Prior to her current field of work, she has almost 10 years of working experience in the automotive industry, working in the fields of mechanical, industrial and process engineering, and procurement. Ms Salbiah Yaakop graduated with a BSc in Biomedical Engineering from Marquette University, USA. In total, she has more than 28 years of working experience.
  • Wan Nurhalimah Binti Wan Abdullah
    Assistant Director from Corporate Communication Unit, Medical Device Authority...

    Wan Nurhalimah Binti Wan Abdullah Assistant Director, Corporate Communication Unit, Medical Device Authority Malaysia

    Assistant Director from Corporate Communication Unit, Medical Device Authority Malaysia, Master in Mass Communication from University Teknologi Mara (UiTM) Malaysia

Partners


Aillis Inc. is a Tokyo-based startup developing an AI device for early and accurate detection of influenza. Although the flu is a common infectious disease, it changes rapidly and there are still many challenges in diagnosis. The device Aillis is developing takes a completely new approach using deep-learning techniques to identify influenza follicles — blister-like swellings that are early indicators of the disease from throat images.


Allied Telesis Group researches and develops IP technologies and network systems and sells them to customers worldwide, while also providing support services. The Group aspires to create a society where people can access information comfortably and safely anytime from anywhere through leading-edge technologies and solutions.

Allied Telesis provides excellent switching and routing with flexibility and cost effectiveness.


Allm (a portmanteau of the phrase ‘All Medical’) is a company dedicated to empowering society by shaping healthcare. We aim to support and empower society by providing cloud-based technologies and secure communication platforms for the healthcare industry. The Allm Platform can be used throughout the patient journey, guiding both patients as well as medical professionals even before the patient reaches the hospital. The platform permits and the integration of data unlike any other, allowing efficient data sharing and smooth handoffs.

Join is the hub for healthcare professionals and providers. It simplifies communication and collaboration between clinicians and healthcare providers through its secure and compliant patient information sharing technology. Join also enables clinicians to view high-resolution CT/MRI images via a DICOM viewer anywhere, reducing the need for them to switch between sites and helping speed up care delivery without sacrificing quality. Join easily integrates into internal IT systems such as PACS and EMR*, enabling users to view and share EHR information, various diagnostic images, laboratory data, and prescriptions. Join is also certified as a software medical device by PMDA (Japan), FDA (United States), CE (European Economic Area), and ANVISA (Brazil).


Asia Africa Investment and Consulting(AAIC) aims to invest in fast growing companies within the Healthcare sector in Asia and Africa. The focus will be to provide growth capital as well as long term value to assist companies in improving their performance and expansion. AAIC currently manages the Africa Health Care Fund “AHF”. Established in 2017, the fund invests specifically in the healthcare sector of Africa.

Create a sustainable growth model. Synergize Japan’s strength with developing country growth-combine
people, funds, knowledge and information. Realize a mutually beneficial relationship for Japan and developing countries, providing all necessary support to ensure the sustainability of the companies we invest in.

Shaping the future together. Establish an extensive team whose experience and contacts will provide market insights and relationships critical to the ability to execute investments and add value to portfolio companies


Epredia was established in July 2019 through an acquisition by PHC Group from Thermo Fisher Scientific. Powered by trusted brands such as Shandon, Microm, Menzel Gläser and Richard-Allan Scientific, Epredia has a wide breadth of solutions that have and will continue to transform the anatomical pathology market. Today, we’re a global precision cancer diagnostics company working to improve patient outcomes by providing groundbreaking technologies. Since our humble beginnings in 1937, every product developed has been impacted by generations of employees who are committed to improving lives by enabling pathologists through enhancing precision cancer diagnostics.


Fujifilm was established as a photographic film manufacturer in 1934. Based on film technologies, we have been expanding our business globally from photography to digital camera, graphic art, highly functional materials and especially focusing on healthcare like medical system.

Regarding Medical systems, we started producing medical X-ray film in 1934, since then we have developed business with an extensive range of digital X-ray, mammography, endoscopes, ultrasound, Dry chemistry and medical IT system.

In Asia, we have regional head office in Singapore and subsidiaries in many Asian countries. In addition to the sales activities, we are also focusing on the education and training of doctors, radiographers and engineers.

We, from now on and forever, continue to provide our medical equipment utilizing our cutting edge technology and the human skill development program and to contribute stabilizing quality healthcare service all over the world.


Since 1953, Hakuzo Medical has been fully supporting those working on the front lines of healthcare. By listening closely to the needs of medical professionals, Hakuzo supplies a range of high-quality sanitary materials for hospitals, health clinics and nursing homes, including infection control products, surgical/gauze-related products, bandages, absorbent cotton, gynecology-related products and nursing care materials.

Having set up a sales office in Thailand two years ago, Hakuzo’s first overseas production plant which is located in Thailand started its production in February 2021 to supply more competitively priced products in the region. This has served as a milestone for Hakuzo in its quest to become a pioneer in infection control in Southeast Asia. Hakuzo is currently exporting to more than 20 countries and the list keeps growing. Japan produces some of the best medical products in the world, and we strongly believe that our medical products can be very successful overseas with the right strategy.


Japan International Hospitals (JIH) system is an initiative to provide information useful to international patients living in various countries, on hospitals in Japan where they may receive medical services, and information on travel assistance to help them. It is not easy for them to seek information on Japan’s hospitals that provide appropriate medical services according to their symptoms, conditions, and diseases. To solve these problems, the Japanese government published the guidelines for developing an environment where international patients can receive medical services in Japan. The guidelines prescribe the requirements be met by hospitals that actively accept international patients. The guidelines also prescribe the requirements to accredit medical travel assistance companies that provide high-quality and comprehensive international patient services.

As a certification body prescribed in the guidelines, MEJ established the criteria for assessing a hospital from aspects of the quality and safety of medical services and the system and efforts of hospital to accept international patients and then recommend the hospital that has met the criteria. MEJ also provides the list of recommended hospitals and information of each hospital on medical care, health check-ups, and medical examinations to be provided to international patients.

Each hospital has many clinical services and departments. However, not all clinical services and departments accept international patients. This website provides the function to find hospitals with clinical services and departments to accept international patients with specified diseases.


KAIGO Life is Japanese healthcare consortium and consulting that promote top Japanese healthcare products and service to Thailand, B2B, B2G and G2G activity to contribute Thailand and Japan.


Matsunaga is Japanese top wheelchair manufacturer that promote high quality and good design Japanese healthcare products to contribute to the well being of Thai nations.


Consulting & Business development service for the innovative company in the medical / healthcare industry, especially for Global expansion and Global open innovation. MEPLA is becoming the “MEdical PLAtform” to make the healthcare innovation to bring great care to all the people in the world.


Nihon Kohden’s mission is to utilize its leading edge technology and products to support medical treatment in all clinical areas from emergency response to testing, diagnosis, treatment and rehabilitation. In addition to clinical treatment, Nihon Kohden products play an active role outside the hospital, such as in health improvement and home medical care and nursing as well as basic medical research.


Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping detect, prevent, and treat disease, furthering scientific research, and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 35,000 employees worldwide in nearly 40 countries and regions.


The PHC Group provides products and services for diabetes management, life sciences and diagnostics, as well as enhanced healthcare services that are used by patients, healthcare professionals and researchers in over 125 countries. By integrating digital solutions with our expertise in precision technology that has been nurtured over decades, we provide the best-in-class devices and services for advancing basic research, diagnosis and medical treatment.


PT Asa Bestari Citta aims to solve problems during pregnancy, childbirth, and childcare in partnership with medical institutions through the Digital Mother and Child Handbook: DiaryBunda.


Roland Berger is an independent company, solely owned by our Partners, who are responsible for overall corporate performance and business success.

Founded in 1967, Roland Berger remains the only leading global consultancy firm with non-Anglo-Saxon roots.

We are German by origin, European by nature and global by ambition, including a strong footprint in Asia and other geographies where we feel that we can truly make an impact.


The Sakura Group has held the leading positions in the infection control and pathology/cytology business arenas. The logo of “Sakura Global Holding Co., Ltd.” consists of a “sakura” or “cherry blossom”, indicative of the Sakura Group along with three circles that indicate the market and business domain. The market represented by the three circles signifies North and South America, Japan and other Asian countries, and Europe, the Middle East and Africa, In addition, the business domain represented by the three circles encompasses (1) cleaning and sterilization for industry use, (2) cleaning and sterilization for medical use, and (3) the pathology and cytology business arenas. The Sakura Group will realize new challenges.


Sumitomo Heavy Industries was founded in 1888 (Meiji 21) as a machine shop when it started manufacturing and repairing machinery and tools used at the Besshi Cooper Mine. Since then, we have grown in line with the development of society and industry.

Today, the Sumitomo Heavy Industries Group is a comprehensive machinery maker that manufactures goods ranging from general machinery and advanced precision machinery to construction machinery, ships, and environmental plant facilities. We utilize the spirit of “product making” that we have developed over the past 100 years to make advancements in various fields including nanotechnology and megastructures. In addition, through the use of precision technologies that “move and control”, we are able to contribute to making society a more harmonious place to live in.

Under our management philosophy, the Sumitomo Heavy Industries Group has made it our corporate mission to become a manufacturer and provider of first-class products and services to the world. Our hope is that by providing high-quality products and solutions backed by tested technologies to customers worldwide, we can support society as well as its industrial foundation, and in turn make the lives of people easier.

As we continue on the path to achieve this goal, we look forward to your continued support and cooperation.


Sysmex is a leader in the diagnostics (IVD) field and has the world’s No. 1 market share in hematology, coagulation and sediment urinalysis. Since its establishment in 1968, Sysmex has expanded its business operations from R&D to production, sales, and service and support. Today, we have more than 60 Group companies globally, providing sales and service to customers in more than 190 countries. To provide tests that deliver more value to patients, we have expanded our original business field of hematology to the fields of blood coagulation, urinalysis, immunology, and clinical chemistry. We are also expanding into the life sciences, which focus on cancer and other diseases.

In keeping with the Group’s corporate philosophy, the “Sysmex Way”, Sysmex has adopted “Shaping the advancement of healthcare.” as its mission. By providing high-value diagnostic technologies, Sysmex is committed to building healthier societies around the world.


TA Networking Corporation is a development consultant company involved with international cooperation projects in the field of health and medical care implemented through Japanese Official Development Assistance (ODA) and international organizations. Our main clients are the Japanese Ministry of Foreign Affairs and the Japan International Cooperation Agency (JICA), who are the primary ODA-implementing institutions. Bringing together experts who have been active for many years in fieldwork for international cooperation, our company was founded in September 2000 to develop the home ground from which experts can demonstrate their skills to the fullest extent.

We have the following two visions as a development consultant company involved in the international cooperation project in developing countries.
1. To nurture the power of peace through fieldwork in international cooperation projects.
2. To increase transparency in the field of international cooperation and share the results of our cooperation with local populations.

After establishment of our company, we have been pioneers in implementing the scheme for technical cooperation projects in the health sector through our Project for Strengthening Medical Management System for Quality Health Services in the State for Eritrea (2008-2011) and Project on Human Resource Development for Health in South Sudan (2009-2013).


Company Mission: From “measuring healthiness” to “creating healthiness”
Our mission is to contribute to netter health for the people of the world through “measuring and monitoring”


Teijin Nakashima Medical is manufacturing and distributing orthopaedic implants such as joint prostheses, spinal fixation systems and trauma devices. We have been dedicating to develop the implants for Japanese and Asian people in the market occupied mostly by the U.S. products. We will create a better life with improving QOL (Quality of Life) by using biocompatible materials and developing suitable design for Asian people’s bony shape and lifestyle.


Terumo is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments including pharmaceuticals, nutritional food supplement, blood bags, disposable medical devices, cardiovascular systems, vascular grafts, peritoneal dialysis, blood glucose monitoring system, medical electronic, and digital thermometers. Terumo will further strive to be of value to patients, medical professionals, and society at large.


Aims to be a comprehensive manufacturer of tatami (Japanese straw mats) making machines and welfare equipment by applying the top tatami-related technologies to the welfare field. Nowadays in-house (in -hospital) infection is considered a serious problem. TOKAISUN is appropriated to infection control and prevention prevention. In the disinfection process, TOKAISUN do not use any drugs containing toxicity with side reactions to the human body and environment. It’s helping make a clean environment to the patients and to the workers.


Ubie develops and operates products that support people involved in healthcare and those receiving healthcare with the mission of “To develop a healthcare guide for everyone”.

There are many challenges in the medical field today that hinder people from receiving medical care. For example, there is an excessive workload of healthcare professionals. There are uncertainties in the content of patient interviews and medical records due to the nature of the language, and this places a burden on the doctors who read and write them. In addition, the workload on medical staff is enormous because a lot of manual documentation works are needed. These workloads are not only lowering the quality of life of medical staff, but also leading to problems such as not being able to provide sufficient clinical education in the field, patients losing the opportunity to find the right treatment.

We are a provider of remote image diagnosis support services and other services that help medical practices run smoothly.

Our company handles medical image management systems, and remote image reading, remote medicine, and home healthcare support systems. Our lines of business include providing remote image diagnosis services, and development, production and sales of PACS with remote medicine support functionality. We provide international image diagnosis support services, and provide medical tourism support services. The main characteristic of our system is its product design. Our system smoothly links with other systems through a broad range of functions and stable behavior. We have obtained an international patent for this system. We also received the Top 100 SMEs in Active IT Use in Business award from the Ministry of Economy, Trade and Industry (METI) in 2015.